Gain Therapeutics climbs on narrower-than-expected quarterly loss

Gain Therapeutics

11/08/2026 15:26

** Shares of drug developer Gain Therapeutics GANX.O rise 5.4% to $1.86 
** GANX reports Q2 loss of 11 cents/shr vs analysts' average loss estimate of 14 cents/shr, according to LSEG data
** Co's R&D expense decreased by $0.6 million to $2.1 million for the three months ended June 30, compared to $2.8 million a year ago
** Analysts on average expected R&D expense of $3.18 million
** Co's cash and its equivalents were $13.1 million as of June 30, compared to $20.8 million as of December 31, 2025
** Including session's move, stock down 42.5% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))